Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751563 | 0.96 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL5751566 | 0.96 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL294341 | 0.86 | ALDH1A1 (0.73) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL8069055 | 0.84 | ALDH1A1 (0.70) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL1011103 | 0.82 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL338280 | 0.82 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL27712861 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL11358902 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL5751558 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| Potassium Ion SCHEMBL10879286 | 0.80 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109867679-B | Preparation method of piricaconide hydrochloride intermediate | 杭州瀚康生物医药科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| EP-1878493-B1 | Method of making a polyisocyanurate/polyurethane foam using carbocation compounds as trimerization catalysts | AIR PROD & CHEM (US) | 2013-08-21 | — | — | EP | claimed |
| US-8445555-B2 | Stabilized carbanions as trimerization catalysts | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2013-05-21 | — | — | US | claimed |
| US-20080015274-A1 | Stabilized carbanions as trimerization catalysts | EVONIK OPERATIONS GMBH (DE) | 2008-01-17 | — | — | US | claimed |
| EP-1878493-A1 | Stabilized carbanions as trimerization catalysts | Air Products and Chemicals, Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-110845482-B | Process for preparing indole compounds | 日本烟草产业株式会社 | 2024-01-19 | — | — | CN | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2022235698-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-110099893-B | Preparation method of droxidopa and intermediate thereof | 广东东阳光药业有限公司 | 2022-09-27 | — | — | CN | disclosed |
| EP-3661931-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-06-10 | — | — | EP | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20080015274-A1 | Stabilized carbanions as trimerization catalysts | EVONIK OPERATIONS GMBH (DE) | 2008-01-17 | — | — | US | disclosed |
| EP-1878493-A1 | Stabilized carbanions as trimerization catalysts | Air Products and Chemicals, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | ALDH1A1 1062/4885MAPK1 1315/4885L3MBTL1 3870/4885 |
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | ALDH1A1 783/4885MAPK1 2140/4885L3MBTL1 2527/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | ALDH1A1 3345/4885MAPK1 3491/4885L3MBTL1 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.